Published in AIDS on August 01, 1996
Genotypic testing for human immunodeficiency virus type 1 drug resistance. Clin Microbiol Rev (2002) 3.27
Worldwide evaluation of DNA sequencing approaches for identification of drug resistance mutations in the human immunodeficiency virus type 1 reverse transcriptase. J Clin Microbiol (1999) 2.63
Viremia, resuppression, and time to resistance in human immunodeficiency virus (HIV) subtype C during first-line antiretroviral therapy in South Africa. Clin Infect Dis (2009) 2.25
2014 Update of the drug resistance mutations in HIV-1. Top Antivir Med (2014) 2.22
A novel polymorphism at codon 333 of human immunodeficiency virus type 1 reverse transcriptase can facilitate dual resistance to zidovudine and L-2',3'-dideoxy-3'-thiacytidine. J Virol (1998) 1.92
In vivo evidence for instability of episomal human immunodeficiency virus type 1 cDNA. J Virol (2005) 1.80
Pre-exposure prophylaxis and antiretroviral resistance: HIV prevention at a cost? Clin Infect Dis (2011) 1.68
Criteria for drugs used in pre-exposure prophylaxis trials against HIV infection. PLoS Med (2006) 1.34
Fitness comparison of thymidine analog resistance pathways in human immunodeficiency virus type 1. J Virol (2006) 1.32
Population pharmacokinetics of nevirapine, zidovudine, and didanosine in human immunodeficiency virus-infected patients. The National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators. Antimicrob Agents Chemother (1999) 1.32
Sequential emergence and clinical implications of viral mutants with K70E and K65R mutation in reverse transcriptase during prolonged tenofovir monotherapy in rhesus macaques with chronic RT-SHIV infection. Retrovirology (2007) 1.28
Virulence and reduced fitness of simian immunodeficiency virus with the M184V mutation in reverse transcriptase. J Virol (2002) 1.23
The Genetic Basis of HIV-1 Resistance to Reverse Transcriptase and Protease Inhibitors. AIDS Rev (2000) 1.15
Population-based monitoring of HIV drug resistance in Namibia with early warning indicators. J Acquir Immune Defic Syndr (2010) 1.15
Human immunodeficiency virus type 1 reverse transcriptase mutation selection during in vitro exposure to tenofovir alone or combined with abacavir or lamivudine. Antimicrob Agents Chemother (2004) 1.12
ACTG (AIDS Clinical Trials Group) 384: a strategy trial comparing consecutive treatments for HIV-1. Control Clin Trials (2001) 1.07
Mechanisms by which the G333D mutation in human immunodeficiency virus type 1 Reverse transcriptase facilitates dual resistance to zidovudine and lamivudine. Antimicrob Agents Chemother (2007) 1.07
Early virologic failure and the development of antiretroviral drug resistance mutations in HIV-infected Ugandan children. J Acquir Immune Defic Syndr (2011) 1.04
A fossil record of zidovudine resistance in transmitted isolates of HIV-1. Proc Natl Acad Sci U S A (2001) 1.02
Evolution of HIV resistance mutations in patients maintained on a stable treatment regimen after virologic failure. J Acquir Immune Defic Syndr (2006) 1.01
Anti-human immunodeficiency virus type 1 activity and resistance profile of 2',3'-didehydro-3'-deoxy-4'-ethynylthymidine in vitro. Antimicrob Agents Chemother (2005) 0.97
Changing patterns in the selection of viral mutations among patients receiving nucleoside and nucleotide drug combinations directed against human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother (2005) 0.90
Differential maintenance of the M184V substitution in the reverse transcriptase of human immunodeficiency virus type 1 by various nucleoside antiretroviral agents in tissue culture. Antimicrob Agents Chemother (2004) 0.88
Phenotypic and genotypic analysis of biologically cloned human immunodeficiency virus type 1 isolates from patients treated with zidovudine and lamivudine. Antimicrob Agents Chemother (2002) 0.87
Antiretroviral genotypic resistance mutations in HIV-1 infected Korean patients with virologic failure. J Korean Med Sci (2009) 0.85
A new point mutation (P157S) in the reverse transcriptase of human immunodeficiency virus type 1 confers low-level resistance to (-)-beta-2',3'-dideoxy-3'-thiacytidine. Antimicrob Agents Chemother (1999) 0.84
International cohort analysis of the antiviral activities of zidovudine and tenofovir in the presence of the K65R mutation in reverse transcriptase. Antimicrob Agents Chemother (2010) 0.82
HIV-1 drug resistance and resistance testing. Infect Genet Evol (2016) 0.80
HIV antiretroviral resistance mutations among antiretroviral treatment-naive and -experienced patients in South Korea. AIDS Res Hum Retroviruses (2013) 0.79
K65R-associated virologic failure in HIV-infected patients receiving tenofovir-containing triple nucleoside/nucleotide reverse transcriptase inhibitor regimens. MedGenMed (2004) 0.79
The use of preexposure treatments for HIV prophylaxis. HIV AIDS (Auckl) (2012) 0.78
HIV drug resistance testing among patients failing second line antiretroviral therapy-Comparison of in-house and commercial sequencing. J Virol Methods (2016) 0.75
Use of the l1 norm for selection of sparse parameter sets that accurately predict drug response phenotype from viral genetic sequences. AMIA Annu Symp Proc (2005) 0.75
A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med (1997) 17.51
Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med (1997) 10.62
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature (2012) 7.76
Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. Veterans Affairs Cooperative Study Group on AIDS. N Engl J Med (1996) 7.06
Reduction of concentration of HIV-1 in semen after treatment of urethritis: implications for prevention of sexual transmission of HIV-1. AIDSCAP Malawi Research Group. Lancet (1997) 6.34
Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med (1999) 5.32
Potent antiretroviral treatment of HIV-infection results in suppression of the seminal shedding of HIV. The Swiss HIV Cohort Study. AIDS (2000) 4.91
A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med (1995) 4.84
Viral burden in genital secretions determines male-to-female sexual transmission of HIV-1: a probabilistic empiric model. AIDS (2001) 4.76
Characterization of V3 sequence heterogeneity in subtype C human immunodeficiency virus type 1 isolates from Malawi: underrepresentation of X4 variants. J Virol (1999) 4.16
Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. North American HIV Working Party. N Engl J Med (1995) 3.86
Cooperation, control, and concession in meerkat groups. Science (2001) 3.79
Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med (2001) 3.78
Use of evolutionary limitations of HIV-1 multidrug resistance to optimize therapy. Nature (1993) 3.73
Maximizing sensitivity and specificity of PCR by pre-amplification heating. Nucleic Acids Res (1991) 3.56
High levels of human immunodeficiency virus type 1 in blood and semen of seropositive men in sub-Saharan Africa. J Infect Dis (1998) 3.46
Effect of antiviral treatment on the shedding of HIV-1 in semen. AIDS (1997) 3.42
Clinical utility of surface EMG: report of the therapeutics and technology assessment subcommittee of the American Academy of Neurology. Neurology (2000) 3.42
Development of a measure of physical function for patients with bone and soft tissue sarcoma. Qual Life Res (1996) 3.40
ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results. AIDS (2001) 3.35
Trichosporon beigelii, an emerging pathogen resistant to amphotericin B. J Clin Microbiol (1990) 2.99
Effect of continuous intravenous infusion of zidovudine (AZT) in children with symptomatic HIV infection. N Engl J Med (1988) 2.68
Extended lamivudine retreatment for chronic hepatitis B: maintenance of viral suppression after discontinuation of therapy. Hepatology (1999) 2.64
Sexual transmission of HIV: infectiousness and prevention. AIDS (1999) 2.59
Quantification of HIV in semen: correlation with antiviral treatment and immune status. AIDS (1997) 2.51
Recurrent Clostridium difficile disease: epidemiology and clinical characteristics. Infect Control Hosp Epidemiol (1999) 2.40
Resistance to 2',3'-dideoxycytidine conferred by a mutation in codon 65 of the human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother (1994) 2.24
Quantitation of human immunodeficiency virus type 1 RNA in cell free seminal plasma: comparison of NASBA with Amplicor reverse transcription-PCR amplification and correlation with quantitative culture. J Virol Methods (1996) 2.12
The search for a better treatment for recurrent Clostridium difficile disease: use of high-dose vancomycin combined with Saccharomyces boulardii. Clin Infect Dis (2000) 2.06
Second-line treatment in the Malawi antiretroviral programme: high early mortality, but good outcomes in survivors, despite extensive drug resistance at baseline. HIV Med (2010) 2.00
Two-drug combinations of zidovudine, didanosine, and recombinant interferon-alpha A inhibit replication of zidovudine-resistant human immunodeficiency virus type 1 synergistically in vitro. J Infect Dis (1991) 1.93
Methane in lake kivu: new data bearing on its origin. Science (1973) 1.92
Mount st. Helens volcano: recent and future behavior. Science (1975) 1.89
3-year suppression of HIV viremia with indinavir, zidovudine, and lamivudine. Ann Intern Med (2000) 1.88
Changing prevalence of oral manifestations of human immuno-deficiency virus in the era of protease inhibitor therapy. Oral Surg Oral Med Oral Pathol Oral Radiol Endod (2000) 1.79
Distant effects of locally injected botulinum toxin: a double-blind study of single fiber EMG changes. Muscle Nerve (1991) 1.77
The effect of Plasmodium falciparum malaria on HIV-1 RNA blood plasma concentration. AIDS (1999) 1.76
THE AGE OF SALT MARSH PEAT AND ITS RELATION TO RECENT CHANGES IN SEA LEVEL AT BARNSTABLE, MASSACHUSETTS. Proc Natl Acad Sci U S A (1962) 1.76
Writing to referring doctors after a new patient consultation. What is wanted and what was contained in letters from one medical oncologist? Aust N Z J Med (1995) 1.75
Granulocyte colony-stimulating factor enhances the phagocytic and bactericidal activity of normal and defective human neutrophils. J Infect Dis (1991) 1.70
Antiretroviral-drug concentrations in semen: implications for sexual transmission of human immunodeficiency virus type 1. Antimicrob Agents Chemother (1999) 1.68
Treatment with amprenavir alone or amprenavir with zidovudine and lamivudine in adults with human immunodeficiency virus infection. AIDS Clinical Trials Group 347 Study Team. J Infect Dis (1999) 1.67
Stimulatory effect of counterflow centrifugal elutriation in large-scale separation of peripheral blood monocytes can be reversed by storing the cells at 37 degrees C. J Clin Apher (1991) 1.61
Simultaneous vs sequential initiation of therapy with indinavir, zidovudine, and lamivudine for HIV-1 infection: 100-week follow-up. JAMA (1998) 1.59
Primary hyperparathyroidism: new concepts in clinical, densitometric and biochemical features. J Intern Med (2005) 1.58
Neurogenic orthostatic hypotension: a double-blind, placebo-controlled study with midodrine. Am J Med (1993) 1.54
The child with cancer and infection. I. Empiric therapy for fever and neutropenia, and preventive strategies. J Pediatr (1991) 1.51
The clinical significance of bundle branch block complicating acute myocardial infarction. 1. Clinical characteristics, hospital mortality, and one-year follow-up. Circulation (1978) 1.48
Strength training increases insulin action in healthy 50- to 65-yr-old men. J Appl Physiol (1985) (1994) 1.46
A phase I/II study of 2'-deoxy-3'-thiacytidine (lamivudine) in patients with advanced human immunodeficiency virus infection. J Infect Dis (1995) 1.46
An apparent phaeochromocytoma and abnormal thyroid function tests. Ann Clin Biochem (2008) 1.46
Leptotrichia buccalis bacteremia in patients with cancer: report of four cases and review. Rev Infect Dis (1991) 1.46
A prospective randomized trial comparing the infectious and noninfectious complications of an externalized catheter versus a subcutaneously implanted device in cancer patients. J Clin Oncol (1992) 1.45
Metastatic breast tumors imitating primary colonic malignancies. Isr Med Assoc J (2000) 1.45
Association of CD4 cell depletion and elevated blood and seminal plasma human immunodeficiency virus type 1 (HIV-1) RNA concentrations with genital ulcer disease in HIV-1-infected men in Malawi. J Infect Dis (1998) 1.42
Electrophysiologic changes in lumbar spinal cord after cervical cord injury. Neurology (1992) 1.42
Effects of preventive, early, and late antifungal chemotherapy with fluconazole in different granulocytopenic models of experimental disseminated candidiasis. J Infect Dis (1990) 1.41
Would I choose dentistry again? N Y State Dent J (1991) 1.40
Combined central and peripheral myelinopathy. Neurology (1987) 1.40
Reliability and validity of an algorithm for fuzzy tissue segmentation of MRI. J Comput Assist Tomogr (1998) 1.40
Detection and biologic characterization of infectious HIV-1 in semen of seropositive men. AIDS (1994) 1.38
Effects of genital tract inflammation on human immunodeficiency virus type 1 V3 populations in blood and semen. J Virol (2000) 1.38
Pharmacokinetics of lamivudine administered alone and with trimethoprim-sulfamethoxazole. Clin Pharmacol Ther (1996) 1.37
Sexual transmission during the incubation period of primary HIV infection. JAMA (2001) 1.37
A phase II trial of nerve growth factor for sensory neuropathy associated with HIV infection. AIDS Clinical Trials Group Team 291. Neurology (2000) 1.35
Comparison of NucliSens and Roche Monitor assays for quantitation of levels of human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol (1999) 1.32
Nucleoside analogues achieve high concentrations in seminal plasma: relationship between drug concentration and virus burden. J Infect Dis (1999) 1.32
Pharmacokinetics and tissue penetration of Sch 39304 in granulocytopenic and nongranulocytopenic rabbits. Antimicrob Agents Chemother (1989) 1.30
Non-syndromic progressive hearing loss DFNA38 is caused by heterozygous missense mutation in the Wolfram syndrome gene WFS1. Hum Mol Genet (2001) 1.29
Strength training increases resting metabolic rate and norepinephrine levels in healthy 50- to 65-yr-old men. J Appl Physiol (1985) (1994) 1.29
HIV-1 viral load in blood, semen and saliva. AIDS (1997) 1.27
The clinical significance of bundle branch block complicating acute myocardial infarction. 2. Indications for temporary and permanent pacemaker insertion. Circulation (1978) 1.26
Purification, toxicity, and antiendotoxin activity of polymyxin B nonapeptide. Antimicrob Agents Chemother (1989) 1.25
Effects of gonadal steroid suppression on skeletal sensitivity to parathyroid hormone in men. J Clin Endocrinol Metab (2001) 1.25
Population pharmacokinetics of lamivudine in adult human immunodeficiency virus-infected patients enrolled in two phase III clinical trials. Antimicrob Agents Chemother (1999) 1.25
Analysis of terminal structures of RNA from potato virus X. Nucleic Acids Res (1978) 1.24
U.S. Geological Survey Radiocarbon Dates IV. Science (1958) 1.24
The use of immunohistochemistry in distinguishing reactive from neoplastic mesothelium. A novel use for desmin and comparative evaluation with epithelial membrane antigen, p53, platelet-derived growth factor-receptor, P-glycoprotein and Bcl-2. Histopathology (2003) 1.21
Prototype trial design for rapid dose selection of antiretroviral drugs: an example using emtricitabine (Coviracil). J Antimicrob Chemother (2001) 1.20
Prospective study of the incidence, timing and treatment of pouchitis in 104 consecutive patients after restorative proctocolectomy. Arch Surg (1996) 1.20
Simultaneous determination of lamivudine and zidovudine concentrations in human seminal plasma using high-performance liquid chromatography and tandem mass spectrometry. J Chromatogr B Biomed Sci Appl (2000) 1.19
Aspects of calcium-activated chloride currents: a neuronal perspective. Pharmacol Ther (1995) 1.18
Vasculitic and encephalitic complications associated with Coccidioides immitis infection of the central nervous system in humans: report of 10 cases and review. Clin Infect Dis (1992) 1.18
Strong and macroporous calcium phosphate cement: Effects of porosity and fiber reinforcement on mechanical properties. J Biomed Mater Res (2001) 1.17
Wear and mechanical properties of nano-silica-fused whisker composites. J Dent Res (2004) 1.17
Transdermal delivery of antisense oligonucleotides with microprojection patch (Macroflux) technology. Pharm Res (2001) 1.16
Serum and cerebrospinal fluid pharmacokinetics of intravenous and oral lamivudine in human immunodeficiency virus-infected children. Antimicrob Agents Chemother (1998) 1.16
Lessons learned from the design and implementation of myocardial infarction adjudication tailored for HIV clinical cohorts. Am J Epidemiol (2014) 1.14
Prostatic neoplasia in transgenic mice with prostate-directed overexpression of the c-myc oncoprotein. Prostate (2000) 1.12
Lamivudine in children with human immunodeficiency virus infection: a phase I/II study. The National Cancer Institute Pediatric Branch-Human Immunodeficiency Virus Working Group. J Infect Dis (1996) 1.11
Multicolour FISH and quantitative PCR can detect submicroscopic deletions in holoprosencephaly patients with a normal karyotype. J Med Genet (2005) 1.11
Involvement of p27KIP1 in G1 arrest mediated by an anti-epidermal growth factor receptor monoclonal antibody. Oncogene (1996) 1.11
Motor neuropathy due to docetaxel and paclitaxel. Neurology (1996) 1.08
Effects of antifungal agents on the function of human neutrophils in vitro. Antimicrob Agents Chemother (1990) 1.08
Petroleum pollutants in surface and groundwater as indicated by the carbon-14 activity of dissolved organic carbon. Science (1975) 1.07
Loss of infectivity ex vivo in plasma of human immunodeficiency virus-infected patients correlates with a high CD4 cell count. J Infect Dis (1993) 1.06